Bio-Rad Bio-Plex Pro™ RBM Canine Kidney Toxicity Assays - Manual (Page 3)

1
Introduction
Early and Accurate Detection of Kidney Toxicity
Acute kidney injury (AKI) is frequently caused by trauma to the kidney due
to drug exposure, an accident, or blood loss from a medical procedure.
In contrast, chronic kidney injury (CKI) results from long-term diseases
such as diabetes, high blood pressure, or from an inherited syndrome.
Early detection of AKI along with proper treatment regimens is critical
in the prevention of further loss of kidney function. The Bio-Plex Pro
™
RBM kidney toxicity assays, developed in partnership with Myriad RBM,
comprise a highly relevant set of biomarkers, found in urine, for early
detection and characterization of kidney toxicity or injury. Myriad RBM’s
close collaboration with the Predictive Safety Testing Consortium (PSTC)
was instrumental in the selection of markers found in these panels.
Traditional markers such as serum creatinine (SCr) and blood urea
nitrogen (BUN) are detectable days or weeks after kidney damage has
occurred. The Bio-Plex Pro RBM kidney toxicity assays provide a tool to
detect biomarkers that may reveal damage within hours, allowing drugs to
be efficiently tested in both preclinical and clinical research settings.
Bio-Plex Pro RBM Kidney Toxicity Assays
The Bio-Plex Pro RBM assays are built on magnetic beads to enable
robust quantification of multiple proteins in human, canine, and rat urine
samples. For researchers working with limited sample volume, the
capacity to multiplex in a small sample volume provides an effective option
over the traditional ELISA. The use of magnetic (MagPlex) beads allows
researchers to automate wash steps on a Bio-Plex Pro (or similar) wash
station. Magnetic separation offers greater convenience, productivity, and
reproducibility compared to vacuum filtration.
For more information please visit www.bio-rad.com/bio-plex.